ERBB2 and breast carcinoma: In 2015, the Food and Drug Administration (FDA) approved ibrance to treat (in combination with letrazole) breast cancer patients with human epidermal growth factor receptor 2 (HER2)(-) and estrogen receptor (ER) (+).